Profit Margin: Net Income as a portion of total sales revenue. Calculated as: Net Income / Total Revenues
Protalix BioTherapeutics, Inc. (PLX) had Profit Margin of -12.52% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$52.74M |
|
$-6.60M |
|
$26.99M |
|
$25.75M |
|
$58.24M |
|
$-5.50M |
|
$-0.11M |
|
$-5.61M |
|
$-5.61M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
$-6.60M |
|
$-5.50M |
|
$-4.04M |
|
78.55M |
|
78.55M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$66.67M |
|
$4.88M |
|
$15.67M |
|
$82.35M |
|
$26.52M |
|
-- |
|
$7.60M |
|
$34.12M |
|
$48.23M |
|
$48.23M |
|
$48.23M |
|
80.43M |
|
| Cash Flow Statement Financials | |
$-11.99M |
|
$-2.37M |
|
$9.33M |
|
$19.76M |
|
$14.68M |
|
$-5.08M |
|
$2.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.51 |
|
-- |
|
-- |
|
-- |
|
-- |
|
48.82% |
|
-10.43% |
|
-10.43% |
|
-7.65% |
|
-10.63% |
|
|
Profit Margin |
-12.52% |
$-13.63M |
|
-- |
|
-- |
|
-- |
|
0.64 |
|
1.05 |
|
5.97 |
|
61.17 |
|
-13.69% |
|
-13.69% |
|
-8.02% |
|
-13.69% |
|
$0.60 |
|
$-0.17 |
|
$-0.15 |
|